Nemaura Medical (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive affordable and flexible Continuous Glucose Monitor (CGM) for use by persons with diabetes and pre-diabetics, hosted an investor webinar on October 23 at 11 a.m. ET.
In the exclusive presentation, Dr. Faz Chowdhury, CEO, discussed Nemaura’s innovative non-invasive technology, recent positive data reports, and commercialization plans.
Disclosure
Nemaura Medical (NASDAQ: NMRD) is a client of RedChip Companies. NMRD agreed to pay RedChip a monthly cash fee for investor awareness services.
TapImmune Inc. changes name to Marker Therapeutics, Inc.
Commenced trading on NASDAQ on Thurs., Oct. 18, 2018 under ticker symbol "MRKR"
Completes $70 million in concurrent private placement
Company rang NASDAQ closing bell
TapImmune Inc. (NASDAQ: MRKR), last week announced the closing of the previously announced merger with privately-held Marker Therapeutics, Inc. In connection with the merger, TapImmune Inc. changed its name to Marker Therapeutics, Inc., and reincorporated from Nevada into Delaware. The combined company will focus on the continued development and commercialization of T cell therapies. Beginning Oct. 18, 2018, the Company's stock will began under the new ticker symbol "MRKR" on the NASDAQ and obtained a new CUSIP number: 57055L 107.
Why It Matters: Marker Therapeutics is in four active Phase 2 clinical trials (six clinical trials in total) in the $100+ billion market for immunotherapy cancer drugs. The global market for cancer drugs is projected to top $150 billion by 2020 (IMS Health), and much of the growth is being driven by constant innovations in cancer immunotherapy. Currently, the company is advancing its robust mid-stage clinical pipeline focused on breast and ovarian cancer.
In May 2018, the Company, then known as TapImmune (TPIV), announced a merger agreement with Marker Therapeutics, creating a transformational Immuno-Oncology Platform. This merger adds Multi-Antigen Targeted Cell Therapy Platform to MRKR’s Peptide Vaccine Portfolio and has the potential to disrupt the CAR-T and TCR filed therapies. MRKR’s acquired therapies are significantly less toxic than CAR-T, require no-gene-modification, and high efficacious and extremely durable, without the need for lymphodepletion.
In March 2018, Marker Therapeutics published positive safety results in a Phase 1 trial for ovarian and breast cancer for its lead vaccine candidate MRKR200. This vaccine has been fast-tracked by the FDA with an orphan drug designation. This will allow more frequent interaction with the FDA and the possibility of accelerated review. Similar companies in Phase 2 clinical trials in immuno-oncology have attained much higher valuations, and trade for more than 3x the market cap of MRKR. With its next-generation T-cell vaccine technology, the Company is well-positioned to capture part of the rapidly growing cancer immunotherapy market.
Disclosure
Marker Therapeutics Inc. (NASDAQ: MRKR) is a client of RedChip Companies, Inc. MRKR agreed to pay RedChip Companies, Inc., a monthly cash fee for (4) months of RedChip investor awareness services.
One of Canada’s largest marijuana producers debuted on the New York Stock Exchange on Tuesday.
Edmonton-based Aurora Cannabis (NYSE: ACB) is the third major Canadian cannabis company to go public in the U.S., where marijuana is still an illegal substance in about half of the states.
Aurora will be following in the steps of Tilray (NASDAQ: TLRY), which became the first U.S. marijuana IPO in July, and Canopy Growth (NYSE: CGC), which debuted in the U.S. markets in May.
The move is in line with the international strategy Aurora has been pushing for months now.
“That’s what we’re in the business of doing: We’re inventing the industry not just in Canada but around the world,” Cam Battley, CCO of Aurora Cannabis told Yahoo Canada Finance in May in response to the cannabis company’s merger with MedReleaf. “We know there’s a window of opportunity that’s open right now, and we don’t know when that window is going to shut.
“At some point we anticipate the U.S. will change its regulation and make cannabis federally legal, and when that happens, we want to have an insurmountable lead already established.”
Further to the company’s global expansion plans, it’s rumored to be in talks with Coca-Cola to expand into the cannabis beverage market. While no plans have been announced yet, there are further rumors that Coca-Cola is developing a cannabis beverage group, which makes a partnership with a producer like Aurora extremely plausible.
Aurora’s Canadian stock, in the meantime, took a dive on Monday. While it had recovered from the dip it took on October 17, the day of recreational marijuana legalization in Canada, it has since plunged further, and at the time of publishing, was down more than 16%.
GSRX Industries (OTCQB: GSRX), a developer and operator of retail cannabis dispensaries with expanding operations in cultivation, extraction, and manufacturing of cannabis and cannabinoid products, is expected to announce its third quarter results this week.
As a startup that began generating revenue earlier this year, investors will want to keep an eye out for accelerating growth on a sequential quarter basis.
With several dispensaries coming on line during the third quarter, it’s likely the company will announce solid double-digit or even triple-digit growth.
Longer-term, under the guidance of former Macy’s Midwest Chairman and CEO Les Ball, GSRX could potentially build a leading cannabis brand, providing significant rewards to early investors that own the stock under $2-$3 per share.
Disclosure
GSRX Industries (OTCQB: GSRX) is a client of RedChip Companies. RedChip Companies, Inc. received 1,000,000 registered shares of GSRX for consulting services and 50,000 shares for investor awareness services. Be advised RedChip intends to sell some or all of its shares at any time, including when you are buying.
OncoSec Medical Incorporated (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, today announced that it has initiated KEYNOTE-890, a Phase 2 clinical trial for the treatment of late-stage triple negative breast cancer (TNBC) with TAVO (intratumoral plasma encoded IL-12, or tavokinogene telseplasmid, plus electroporation) in combination with Merck's (NYSE: MRK) KEYTRUDA® (pembrolizumab). The initiation of KEYNOTE-890 marks the second Phase 2 trial for OncoSec involving a combination of TAVO and KEYTRUDA®. The first, PISCES/KEYNOTE-695, is a global, multicenter Phase 2b trial of TAVO in combination with KEYTRUDA® for metastatic melanoma.
Why It Matters: KEYNOTE-890 is a multicenter Phase 2 open-label trial of TAVO in combination with KEYTRUDA® in patients with histologically confirmed diagnosis of inoperable locally advanced or metastatic TNBC and at least one prior line of approved systemic chemotherapy or immunotherapy.
The Dow Jones Industrial Average closed 125.98 points lower at 25,191.43, while the S&P 500 fell 0.55% to 2,740.69. The Nasdaq Composite, meanwhile, closed 0.4% lower at 7,437.54. The small-caps Russell 2000 dropped 0.8% and turned negative for the year.
The S&P 500 posted its fifth straight decline and briefly dipped below the lows hit earlier in October during this ongoing sell-off. The major indexes are all down at least 4.7% for October.
The U.S. and China have implemented tariffs on billions of dollars’ worth of their goods this year, increasing costs for companies and raising fears that tighter global trade conditions could slow down the global economy. Negotiations between the two countries have stalled recently, increasing fears that this spat will be prolonged. (Source: CNBC)
Quote of the Week
"If you don't know your way around, you can get slaughtered."
Greg Sichenzia, Founder of Sichenzia, Ross, Friedman and Ference
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on small-cap and mid-cap companies. Since 1992, RedChip has delivered concrete, measurable results for its clients through the most comprehensive service platform in the industry for small-cap and mid-cap companies. These services include a worldwide distribution network for its stock research written by analysts holding the CFA designation; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated over 2.3 million unique investor views; quarterly global online institutional and retail investor conferences that reach over 10,000 investors annually; "The RedChip Money Report" television show which airs in 100 million homes across the U.S. on The Family Channel; a weekly newsletter delivered to 60,000 investors; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that the RedChip Companies Inc. is an investor relations firm hired by certain Companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov.
